Dr. Zingman's clinical interest is in Internal medicine and Clinical Pharmacology, and his research interests are cellular mechanisms of heart failure and arrhythmias, as well as cardioprotection.

Honors, Awards, and Organizations

• 2001 American Society for Clinical Pharmacology and Therapeutics Presidential trainee Award
• 2005 Mayo Clinic Kogod Program on Aging, Award and Grant for “Cardioprotective Kir6.2/SUR2A multimers: Role in aging-associated apoptosis and adaptation response.”

Recent Publications

1. Zingman, L.V., Park, S., Olson, T.M., Alekseev, A.E., Terzic, A. Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy. Clin Pharm Ther 81:99-103, 2007.
2. Olson, T.M., Alekseev, A.E., Liu, X.K., Park, S., Zingman, L.V., Bienengraeber, M., Sattiraju, S., Ballew, J.D., Jahangir, A., Terzic, A. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet. 15:2185-2191, 2006.
3. Zingman, L.V., Hodgson, D.M., Bast, P.H., Kane, G.C., Perez-Terzic, C., Gumina, R.J., Pucar, D., Bienengraeber, M., Dzeja, P.P., Miki, T., Seino, S., Alekseev, A.E., Terzic, A. Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci USA 99: 3278-83, 2002.

Medical School:
First Leningrad Medical Institute

Residency:
First Leningrad City Hospital
Ben Gurion University

Fellowship:
Mayo Graduate School of Medicine